Libloze Luspatercept for Injection

1. Indications and Usage
Anemia in Non-Transfusion-Dependent β-Thalassemia (NTDT):
Indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Anemia in Myelodysplastic Syndromes (MDS):
Indicated for the treatment of anemia in adult patients with lower-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) who have an inadequate response to ESAs and who require RBC transfusions.
2. Dosage and Administration
Route of Administration:
For Subcutaneous Injection ONLY.
Reconstitution:
Reconstitute the lyophilized powder in Sterile Water for Injection. Do not shake or vigorously swirl.
Recommended Dosage (NTDT):
Starting Dose: 1 mg/kg once every 3 weeks.
Dose Adjustment: If transfusion burden does not decrease after at least 2 doses (6 weeks), increase to 1.25 mg/kg.
Maximum Dose: 1.25 mg/kg once every 3 weeks.
Recommended Dosage (MDS-RS):
Starting Dose: 1 mg/kg once every 3 weeks.
Dose Adjustment: If transfusion burden does not decrease after 2 doses, increase by increments (e.g., to 1.33 mg/kg) up to a maximum of 1.75 mg/kg.
Dose Interruption:
Withhold dose if pre-dose hemoglobin is ≥11.5 g/dL (in the absence of recent transfusion). Resume when Hb ≤11 g/dL.
3. Mechanism of Action
Activin Receptor Ligand Trap:
Luspatercept is a recombinant fusion protein that binds to specific ligands in the transforming growth factor-beta (TGF-β) superfamily.
Erythroid Maturation:
It acts as a ligand trap to reduce SMAD2/3 signaling. This promotes late-stage erythroid maturation, thereby improving ineffective erythropoiesis and increasing hemoglobin levels.
4. Safety and Warnings
Hypertension:
Hypertension and hypertensive crisis have been reported. Monitor blood pressure regularly and treat as clinically indicated.
Hypersensitivity Reactions:
Reactions may occur; patients should be observed for signs of anaphylaxis after administration.
Embryo-Fetal Toxicity:
May cause fetal harm based on its mechanism of action.
5. Adverse Reactions
Most Common:
Arthralgia (joint pain), headache, hypertension, dizziness, diarrhea, and fatigue.
Injection Site Reactions:
Pain, erythema, and bruising at the injection site.
6. Drug Interactions
No Specific Interactions:
No formal drug-drug interaction studies have been conducted.
Concomitant Use:
Caution is advised when using with other agents that may affect blood pressure or erythropoiesis.
7. Pharmaceutical Information
Chemical Composition:
Active Ingredient: Luspatercept acetate.
Appearance: White to off-white lyophilized cake.
Storage:
Store at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.